Hematologic and nonhematologic adverse events in 34 patients with CML treated with asciminib
| Event . | Grade 1-2, n (%) . | Grade ≥3, n (%) . |
|---|---|---|
| No. of patients with ≥1 adverse event (n = 10) | ||
| Hematologic toxicities | ||
| Thrombocytopenia | 09 (26.4) | 06 (17.6) |
| Neutropenia | 5 (14.7) | 5 (14.7) |
| Anemia | 0 | 2 (5.8) |
| Nonhematologic toxicities | ||
| Gastrointestinal | ||
| Diarrhea | 1 (2.9) | 0 |
| Constipation | 2 (5.8) | 0 |
| Nausea | 2 (5.8) | 0 |
| Cardiovascular | ||
| Acute myocardial infarction | 0 | 1 (2.9) |
| Hypertension | 0 | 1 (2.9) |
| Others | ||
| Anxiety | 1 (2.9) | 0 |
| Muscular pain | 2 (5.8) | 0 |
| Skin (rash, dryness, or pruritus) | 5 (14.7) | 0 |
| Upper airway infection | 2 (5.8) | 0 |
| Headache | 1 (2.9) | 0 |
| Edema | 1 (2.9) | 0 |
| Laboratory abnormalities | ||
| Increased serum amylase | 1 (2.9) | 0 |
| Increased blood bilirubin | 1 (2.9) | 0 |
| Increased aspartate aminotransferase | 1 |
| Event . | Grade 1-2, n (%) . | Grade ≥3, n (%) . |
|---|---|---|
| No. of patients with ≥1 adverse event (n = 10) | ||
| Hematologic toxicities | ||
| Thrombocytopenia | 09 (26.4) | 06 (17.6) |
| Neutropenia | 5 (14.7) | 5 (14.7) |
| Anemia | 0 | 2 (5.8) |
| Nonhematologic toxicities | ||
| Gastrointestinal | ||
| Diarrhea | 1 (2.9) | 0 |
| Constipation | 2 (5.8) | 0 |
| Nausea | 2 (5.8) | 0 |
| Cardiovascular | ||
| Acute myocardial infarction | 0 | 1 (2.9) |
| Hypertension | 0 | 1 (2.9) |
| Others | ||
| Anxiety | 1 (2.9) | 0 |
| Muscular pain | 2 (5.8) | 0 |
| Skin (rash, dryness, or pruritus) | 5 (14.7) | 0 |
| Upper airway infection | 2 (5.8) | 0 |
| Headache | 1 (2.9) | 0 |
| Edema | 1 (2.9) | 0 |
| Laboratory abnormalities | ||
| Increased serum amylase | 1 (2.9) | 0 |
| Increased blood bilirubin | 1 (2.9) | 0 |
| Increased aspartate aminotransferase | 1 |